Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Prosonix Limited
Prosonix Limited
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Proposed acquisition of Aerocrine and Prosonix by Circassia Pharmaceuticals
Creating a world-class speciality pharmaceutical allergy and asthma business
Research & Development
Prosonix appoints Frank Condella as Non-executive Director
He brings more than 30 years of business experience to the position
Research & Development
Prosonix appoints a Chief Business Officer
To drive business development and commercial strategy
Research & Development
Prosonix receives £1.3m grant from the Biomedical Catalyst
To accelerate development of Multi-component particle (MCP) based combination respiratory medicines
Research & Development
Prosonix collaboration to speed up development of respiratory medicines
Prosonix and Imperial College London to accelerate development of engineered Multi-component Particles
Research & Development
Prosonix appoints chief medical officer
Oxford firm hires respiratory drug development expert Dr Geoff Down
Prosonix appoints first head of regulatory affairs
Rob Crocker joins Oxford, UK firm to take up the new role
Subscribe now